HiberCell’s HC-7366 Gains the US FDA’s Fast Track Designation for Treating Acute Myeloid Leukemia (AML)
Shots:
- The US FDA has granted FTD to HC-7366 (small molecule) for treating adults with r/r AML
- HC-7366 is currently being investigated under P-Ib trial for its safety, tolerability, preliminary efficacy & RP2D to treat r/r AML or MDS AML; the trial may expand to include monotx. & combinations based on these outcomes. It is also being assessed in another P-Ib/II trial combined with belzutifan for clear cell RCC
- HC-7366 works on the GCN2 kinase, responsible for integrated stress response (ISR) pathway which is utilized by the cancer cells for survival. It hyperactivates GCN2, leading to antitumor & immunomodulatory effects alone and combined with SoC in both solid & liquid tumor models
Ref: Global Newswire | Image: HiberCell
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
